GLP1R and X-linked cone dysfunction syndrome with myopia: GLP-1 receptor agonists have known satiety-promoting effects due to central action of the neuropeptide GLP-1 [1], with reduced activation of appetite- and reward-related brain areas in response to food [18]; thus, they were hypothesised as a treatment for BED [19, 20].